Cliical Trials: Oversight of DCT/Hybrid Sites

Risk-Based Oversight of Home Health, Local Labs and Community Providers Risk-Based Oversight of Home Health, Local Labs and Community Providers In the ever-evolving landscape of clinical trials, particularly with the rise of decentralized clinical trials (DCT) and hybrid models, the need for effective risk-based monitoring (RBM) has never been more critical. This article provides a…

Read More “Risk-Based Oversight of Home Health, Local Labs and Community Providers” »

Oversight Models for Decentralized and Hybrid Clinical Trial Sites Oversight Models for Decentralized and Hybrid Clinical Trial Sites The evolution of clinical trials has risen significantly due to technological advancements and changing patient expectations, leading to the emergence of decentralized and hybrid clinical trial models. These models offer potential benefits such as improved patient access…

Read More “Oversight Models for Decentralized and Hybrid Clinical Trial Sites” »

Ensuring GCP Compliance Across Traditional and Virtual Site Footprints Ensuring GCP Compliance Across Traditional and Virtual Site Footprints In the evolving landscape of clinical research, ensuring compliance with Good Clinical Practice (GCP) remains a primary concern for clinical operations, regulatory affairs, and medical affairs professionals. This comprehensive guide outlines the steps necessary to ensure GCP…

Read More “Ensuring GCP Compliance Across Traditional and Virtual Site Footprints” »

Monitoring and Quality Management in DCT and Hybrid Trial Designs In the evolving landscape of clinical research, decentralized clinical trials (DCT) and hybrid trial designs have emerged as essential methodologies, especially in the context of prostate cancer clinical trials. The complexity of these frameworks necessitates robust monitoring and quality management strategies to ensure data integrity…

Read More “Monitoring and Quality Management in DCT and Hybrid Trial Designs” »

Central Monitoring Approaches Tailored to DCT/Hybrid Ecosystems Central Monitoring Approaches Tailored to DCT/Hybrid Ecosystems As clinical trials increasingly adopt decentralized clinical trial (DCT) methodologies and hybrid approaches, the need for robust central monitoring techniques becomes paramount. This article serves as a comprehensive guide for clinical operations, regulatory affairs, and medical affairs professionals, detailing effective central…

Read More “Central Monitoring Approaches Tailored to DCT/Hybrid Ecosystems” »

Oversight Strategies for Direct-to-Patient IP Shipments and Returns Oversight Strategies for Direct-to-Patient IP Shipments and Returns Clinical trials have increasingly embraced direct-to-patient (DTP) strategies, facilitated by advancements in logistics and technology. DTP clinical trials offer significant benefits, including enhanced patient engagement, expanded access to investigational products (IPs), and reduced site burden. However, they introduce unique…

Read More “Oversight Strategies for Direct-to-Patient IP Shipments and Returns” »

Training and Qualification of Non-Traditional Site Staff in DCT Models Training and Qualification of Non-Traditional Site Staff in DCT Models In the evolving landscape of clinical trials, decentralized clinical trial (DCT) models are increasingly becoming the norm. This shift requires thoughtful strategies for the training and qualification of non-traditional site staff. As clinical trials become…

Read More “Training and Qualification of Non-Traditional Site Staff in DCT Models” »

Vendor and Partner Governance for Technology-Enabled DCT Sites Vendor and Partner Governance for Technology-Enabled DCT Sites The landscape of clinical trials is rapidly evolving, particularly with the rise of technology-enabled decentralized clinical trials (DCT). As clinical research organizations (CROs) and sponsors increasingly implement DCT and hybrid models, the need for robust vendor and partner governance…

Read More “Vendor and Partner Governance for Technology-Enabled DCT Sites” »

Documentation of Oversight Responsibilities in Contracts and Quality Agreements Documentation of Oversight Responsibilities in Contracts and Quality Agreements In the dynamic landscape of clinical trials, particularly in the context of decentralized clinical trials (DCT) and hybrid sites, ensuring robust oversight through appropriate documentation is vital. This includes accurately defining oversight responsibilities in contracts and quality…

Read More “Documentation of Oversight Responsibilities in Contracts and Quality Agreements” »